Advice

In the absence of a submission from the holder of the marketing authorisation

peginterferon alfa-2a (Pegasys ®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
peginterferon alfa-2a (Pegasys)
SMC ID:
1312/18
Indication:
Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
12 February 2018